www.dailypolitical.com ·
Pulse Biosciences Q1 Earnings Call Highlights
Topic context
This topic has been covered 415419 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPulse Biosciences is a medical device company focused on its nPulse cardiac catheter for atrial fibrillation. The commercial mechanism is weak at this stage: the company is pre-revenue with a small cash reserve, and the pivotal trial has just begun enrollment. No immediate product launch, revenue, or margin impact is expected in the near term. The primary commercial signal is the progress of clinical trials, which may affect future valuation and partnership opportunities. No direct commodity or supply chain impact.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Pulse Biosciences reported Q1 2026 revenue of $401,000 and GAAP net loss of $18.6 million.
- Cash reserves at $68.3 million.
- nPulse cardiac catheter for atrial fibrillation shows 100% procedure success at six months and 96% at one year (95 subjects).
- Enrollment began in NANOPULSE-AF pivotal trial; first seven patients treated at St. Bernards Medical Center.
- Company plans to complete pivotal trial enrollment by early Q4 2026.
Related stories
fool.com
Canaan Can Q1 2026 Earnings Transcript
fool.com
Keysight Keys Q2 2026 Earnings Transcript
zerohedge.com
New Fed Chair Pledges Regime Change Fight Inflation Heres What Could Mean Practice
fool.com
James Hardie Jhx Q4 2026 Earnings Transcript
lewrockwell.com